Clinical trials
HIV Infections trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
62 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 4 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 50 |
| Active, not recruiting | 5 |
| Terminated | 4 |
| Unknown status | 2 |
| Approved for marketing | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ViiV Healthcare | 21 |
| Boston Medical Center | 9 |
| Bristol-Myers Squibb | 4 |
| Tibotec Pharmaceuticals, Ireland | 4 |
| GlaxoSmithKline | 3 |
| Boehringer Ingelheim | 2 |
| Gilead Sciences | 2 |
| Janssen-Cilag International NV | 2 |
| Merck Sharp & Dohme LLC | 2 |
| Central Clinical Hospital of the Russian Academy of Sciences | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| HIV Infections | 62 |
| Acquired Immunodeficiency Syndrome | 21 |
| Infections | 12 |
| Substance-Related Disorders | 5 |
| Inflammation | 4 |
| Tuberculosis | 3 |
| Hepatitis C | 2 |
| Pain | 2 |
| Sexually Transmitted Diseases | 2 |
| Angina, Stable | 1 |
Trials
Showing 26 to 50 of 62. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.